VBI Vaccines has started enrollment in a Phase 1 clinical study of VBI-2901, a multivalent enveloped virus-like particle (eVLP) coronavirus vaccine candidate targeting SARS, COVID-19 and MERS.
An investigational Alzheimer's drug made by Eisai Co Ltd and Biogen slowed cognitive and functional decline in a trial involving a large group of patients in the early stages of the disease.
The US National Institutes of Health plans to invest $130m in accelerating the widespread use of artificial intelligence (AI) by the biomedical and behavioral research communities through its Bridge2AI program.
San Francisco based Cellares is partnering with Lexington, Massachusetts headquartered iVexSol to accelerate and improve the quality of viral vector manufacturing and transduction.
An extension of a Phase 3 trial for Biogen’s tofersen shows benefits in a form of motor neuron disease, according to a study published in the New England Journal of Medicine (NEJM) this week.
Vaxxas will receive an AU$8.2m second round grant to support the manufacturing scale-up of its technology that enables vaccines to be applied to the skin using a small patch.
Rocket Pharmaceuticals, a late-stage, clinical biotech advancing a pipeline of genetic therapies for rare childhood disorders, will acquire Renovacor: helping it strengthen its position in AAV-based cardiac gene therapy.
Pfizer will submit a Biologics License Application (BLA) for its investigational pentavalent meningococcal vaccine (MenABCWY) to the US Food and Drug Administration (FDA) later this year, following positive top-line results from a Phase 3 trial.
Novo Nordisk and Microsoft have entered a new strategic collaboration to combine Microsoft’s computational services, cloud, and artificial intelligence (AI) with Novo Nordisk’s drug discovery, development, and data science capabilities.
UK-based biopharmaceutical company, PhoreMost, is to deploy its in-house expertise and next-generation phenotypic screening platform, SITESEEKER, toward disease-relevant pathways nominated by Roche.
What role does Bioprocessing 4.0 have to play in the ongoing energy crisis? How can we train and develop the right skills for the industry? These are just some of the questions we’ll ask in our free-to-attend webinar tomorrow!
Experts from the health information specialist explain how the use of RWD and RWE has helped speed up and improve the development of therapies and vaccines.
Technology firm, Benchling, has developed what it calls the biopharma industry’s first set of full capabilities for designing, modelling, and studying both natural and chemically modified RNA in a single platform.
Bioprocessing 4.0 and digitalization is all about embracing new technologies to enable faster, smoother and more efficient biomanufacturing. And that also requires embracing a new mindset.
Ori Biotech, a company aiming to bring automated manufacturing to the CGT industry, has been executing its strategic plan following the US$100m it raised in its Series B funding round earlier this year.
Arcturus Therapeutics has obtained an award for up to $63.2m from the Biomedical Advanced Research and Development Authority (BARDA): allowing the company to expand its current influenza vaccine program to include development of a pandemic influenza vaccine...
As environmental considerations move up the agenda for biopharmaceutical manufacturers, process intensification can offer a win-win situation for those looking to lower costs and improve sustainability.
Process intensification is the natural next step for the biopharma industry as it transitions from a focus on global blockbuster drugs to a diversified portfolio of specialized biopharmaceuticals, finds a study.
The compelling benefits of single-use technologies (SUT) have been demonstrated in bioprocessing for many years. They are deemed to have a role to play in facilitating process intensification through enabling low capital costs and fast change-over time...
BrainVectis, a subsidiary of AskBio, has received clearance from the French authorities to start a Phase 1-2 clinical trial for its novel Huntington’s Disease gene therapy, BV-101.
The WHO has updated its advice on COVID-19 booster doses: including recommendations on which groups should receive a second booster shot and how countries should plan around the upcoming availability of variant-specific vaccines.
West Pharmaceutical Services has made an investment in Latch Medical, a Dublin-based company working on next-generation vaccine and biologics delivery technology.
The AI and QC specialists have joined to use AI and QC in order to discover biological pathways relevant to the treatment of triple-negative breast cancer.
Merck and Orna Therapeutics have announced a collaboration agreement to discover, develop and commercialize Orna’s next generation oRNA technology across multiple programs, including vaccines and therapeutics in infectious disease and oncology.
The pharmaceutical company has inked a strategic collaboration with the drug discovery firm, centering on uncovering novel targets in Alzheimer’s disease.
Biopharmaceutical company Global Blood Therapeutics specializes in conditions that often disproportionately impact underrepresented communities, such as SCD.
BioNTech and Genmab are expanding a global collaboration to develop and commercialize novel immunotherapies for the treatment of cancer patients: with the first monospecific antibody candidate expected to enter clinical trials by the end of the year.
Vaxess Technologies has launched a phase 1 trial for its H1 influenza vaccine patch: outlining its mission to increase access to vaccines via the shelf-stable, sustained-release patch.
With speculation that Merck is lining up a multi-billion dollar acquisition in the ADC space, the company has agreed a second collaboration deal with Sichuan Kelun Pharmaceutical.
Cambridge, Massachusetts based, Alnylam Pharmaceuticals, along with collaborators, has identified mutations in the INHBE gene linked with protection against abdominal obesity.
The US Centers for Disease Control and Prevention (CDC) says COVID-19 has ‘pushed back years of progress’ in combating antimicrobial resistance (AR) in the US – adding that the threat from AR has also got worse.
The Coalition for Epidemic Preparedness Innovations (CEPI) will provide funding of up to $375,000 to the UK Medicines and Healthcare products Regulatory Agency (MHRA) and the UK Health Security Agency (UKHSA) to support the development of laboratory tools...
Moderna and the International Vaccine Institute (IVI) have signed a Memorandum of Understanding (MOU) to establish a partnership for vaccine research and development.
Polpharma Biologics’ Marketing Authorization Application for natalizumab – a proposed biosimilar to Biogen’s Tysabri – has been accepted by the European Medicines Agency (EMA).
Amazon is partnering with the Fred Hutchinson Cancer Research Center on a Phase I trial for a cancer vaccine targeting metastatic melanoma and breast cancer.
A representative from life-science services company Azzur Group explains how flexibility and speed can help in reaching the best solution more efficiently.
Releasing its first-ever report on the pipeline of vaccines in development to prevent infections caused by antimicrobial-resistant (AMR) bacterial pathogens, the WHO is calling for more AMR vaccine development.
Moderna has dosed the first participant in a Phase 1 trial of its Nipah virus vaccine candidate, mRNA-1215, that has been developed in collaboration with the US National Institutes of Health (NIH).
Merck (MSD outside the US and Canada) is welcoming applications from early-stage biomedical start-ups for its newly launched Merck Digital Sciences Studio (MDSS): which seeks to support technologies for drug discovery and development.
